Last updated: 2026-09-09 10:37:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Agios Pharmaceuticals, Inc. (AGIO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $33.53, with a market capitalisation of $1.98B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.24 to $46.00. This page covers its latest market performance, valuation, price trends and company information.
$1.98B | |
$32.53 | |
$138.85 | |
$15.77 | |
$33.10 | |
610.61K | |
1.14M | |
-- | |
$46.00 | |
$22.24 | |
-- | |
-- |
Agios Pharmaceuticals, Inc. (AGIO) is trading at $33.25 in pre-market trading as of 2026-09-08 23:31:00, up 0.45% ($0.15) from the previous close of $33.10
Pre-market trading shows how investors are pricing AGIO before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Agios Pharmaceuticals, Inc. (AGIO) moved from $33.32 to $33.53, representing a gain of 0.64% ($0.21).
The stock traded between $32.23 and $34.93 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 734.37 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 47.5%
AGIO is currently trading at $33.53, placing it 47.5% of the way from its 52-week low of $22.24 to its 52-week high of $46.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 540 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Agios Pharmaceuticals, Inc. (AGIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.